Vertex Pharmaceuticals (VRTX) reported Q4 non-GAAP net income late Monday of $3.98 per diluted share, down from $4.20 a year earlier.

Analysts polled by FactSet expected $4.02.

Product revenue for the quarter ended Dec. 31 was $2.91 billion, up from $2.52 billion a year earlier.

Analysts surveyed by FactSet forecast $2.78 billion.

The biotech firm expects fiscal 2025 revenue of $11.75 billion to $12 billion. Analysts polled by FactSet are looking for $11.84 billion.

Shares of Vertex Pharmaceuticals were up 1.2% in after-hours trading.